The long-term program is meant to translate the most promising biomarker(s) into practice. Biomarker development will be supported until the biomarker is implemented on a national scale. This goal should be achieved within the shortest, yet realistic timeframe possible. KWF funding will be adjusted or ceased when the biomarker reaches a stage where further development should be (partially) taken over by a (for profit) third-party. The program is open to any tumor type. A requirement is that there is a clear clinical need for the biomarker in the oncology field. Preferably, the biomarker can be implemented without increasing treatment costs. Also, the biomarker should only have a single context of use. At the end of the program, the biomarker needs to be implemented in clinical practice. The application is preceded by a pre-registration. More information can be found here.
We create scientific impact that leads to innovation in the health and healthcare of the future.
NL
DE
